Ayala Pharm Financials
This page shows Ayala Pharm (ADXS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Ayala’s economics are driven by R&D cash burn, with external financing carrying a business that produced only $13K in FY2023.
From FY2021 to FY2023, operating cash burn nearly doubled from-$15.4M to-$29.5M , showing the business moved further from self-funding rather than closer to it. By FY2023, revenue was just$13K while R&D still consumed$24.1M , so new financing was mainly replacing consumed cash, not rebuilding liquidity.
The balance sheet swung from a cash-heavy posture in FY2021 to negative equity by FY2023; cash was only
FY2023 reads more like a funding bridge than an operating year: financing inflow of
Financial Health Signals
Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Ayala Pharm's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Ayala Pharm has an operating margin of -278969.2%, meaning the company retains $-278969 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -5419.5% the prior year.
Ayala Pharm's revenue declined 98.1% year-over-year, from $692K to $13K. This contraction results in a growth score of 0/100.
Ayala Pharm carries a low D/E ratio of -1.68, meaning only $-1.68 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Ayala Pharm's current ratio of 0.30 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Ayala Pharm passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Ayala Pharm generates $0.61 in operating cash flow (-$29.5M OCF vs -$48.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Ayala Pharm generated $13K in revenue in fiscal year 2023. This represents a decrease of 98.1% from the prior year.
Ayala Pharm's EBITDA was -$35.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 3.9% from the prior year.
Ayala Pharm reported -$48.1M in net income in fiscal year 2023. This represents a decrease of 26.5% from the prior year.
Ayala Pharm earned $-7.99 per diluted share (EPS) in fiscal year 2023. This represents an increase of 39.1% from the prior year.
Cash & Balance Sheet
Ayala Pharm held $4.9M in cash against $0 in long-term debt as of fiscal year 2023.
Ayala Pharm had 12M shares outstanding in fiscal year 2023. This represents an increase of 145.1% from the prior year.
Margins & Returns
Ayala Pharm's gross margin was 0.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is down 13.0 percentage points from the prior year.
Ayala Pharm's operating margin was -278969.2% in fiscal year 2023, reflecting core business profitability. This is down 273549.7 percentage points from the prior year.
Ayala Pharm's net profit margin was -369784.6% in fiscal year 2023, showing the share of revenue converted to profit. This is down 364291.4 percentage points from the prior year.
Capital Allocation
Ayala Pharm invested $24.1M in research and development in fiscal year 2023. This represents a decrease of 13.5% from the prior year.
ADXS Income Statement
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $9K+125.0% | $4K-96.2% | $105K+15.4% | $91K+139.5% | $38K | N/A |
| Cost of Revenue | N/A | N/A | $9K+125.0% | $4K-96.2% | $105K+15.4% | $91K+139.5% | $38K | N/A |
| Gross Profit | N/A | N/A | $0 | $0 | $0 | $0 | $0 | N/A |
| R&D Expenses | N/A | $5.7M-0.7% | $5.7M-21.2% | $7.3M-4.0% | $7.6M+5.1% | $7.2M+29.0% | $5.6M+237.4% | $1.7M |
| SG&A Expenses | N/A | $1.4M-47.6% | $2.8M-40.0% | $4.6M+113.5% | $2.2M-25.2% | $2.9M+26.8% | $2.3M-9.5% | $2.5M |
| Operating Income | N/A | -$7.1M+16.0% | -$8.5M+28.5% | -$11.9M-22.0% | -$9.7M+3.5% | -$10.1M-28.4% | -$7.9M-88.6% | -$4.2M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $65K-48.8% | $127K+103.0% | -$4.2M-5709.3% | $75K-29.2% | $106K-50.5% | $214K | N/A |
| Net Income | N/A | -$7.3M+15.6% | -$8.7M-18.2% | -$7.4M+24.6% | -$9.8M+4.1% | -$10.2M-25.6% | -$8.1M-2121.4% | -$365K |
| EPS (Diluted) | N/A | $-1.53+15.9% | $-1.82 | N/A | N/A | $-3.51-24.0% | $-2.83 | N/A |
ADXS Balance Sheet
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.6M+137.5% | $7.0M-42.5% | $12.2M-42.1% | $21.0M+170.2% | $7.8M-70.0% | $25.9M-13.9% | $30.1M-35.3% | $46.5M |
| Current Assets | $7.5M+65.4% | $4.6M-52.4% | $9.6M-47.7% | $18.3M+472.8% | $3.2M-87.6% | $25.8M-13.6% | $29.8M-30.8% | $43.1M |
| Cash & Equivalents | $4.9M+130.0% | $2.1M-70.0% | $7.1M-58.0% | $16.8M+599.3% | $2.4M-78.5% | $11.2M-44.2% | $20.1M-45.0% | $36.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $4.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $41.0M+210.1% | $13.2M+18.7% | $11.1M-1.6% | $11.3M+27.6% | $8.9M-49.6% | $17.6M+40.0% | $12.6M+237.3% | $3.7M |
| Current Liabilities | $25.0M+193.4% | $8.5M+1.2% | $8.4M-14.3% | $9.8M+58.6% | $6.2M+169.3% | $2.3M+20.8% | $1.9M-48.7% | $3.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$24.4M-291.2% | -$6.2M-718.5% | $1.0M-89.6% | $9.7M+980.3% | -$1.1M-113.2% | $8.3M-52.5% | $17.5M-48.7% | $34.2M |
| Retained Earnings | -$197.2M-14.3% | -$172.6M-4.4% | -$165.2M-5.6% | -$156.5M-4.9% | -$149.2M+66.3% | -$443.0M-1.0% | -$438.4M-2.2% | -$429.0M |
ADXS Cash Flow Statement
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.2M-3.2% | -$7.0M+18.5% | -$8.6M-27.0% | -$6.7M+17.5% | -$8.2M+12.5% | -$9.3M-142.4% | -$3.9M+6.9% | -$4.1M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$66K-13.8% | -$58K |
| Financing Cash Flow | $4.0M+100.0% | $2.0M+266.7% | -$1.2M-105.7% | $21.2M+3547.3% | -$615K-231.4% | $468K+2700.0% | -$18K-100.4% | $4.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ADXS Financial Ratios
| Metric | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0%0.0pp | 0.0% | N/A |
| Operating Margin | N/A | N/A | -94288.9%+202436.1pp | -296725.0%-287463.1pp | -9261.9%+1815.0pp | -11076.9%+9586.2pp | -20663.2% | N/A |
| Net Margin | N/A | N/A | -96655.6%+87369.4pp | -184025.0%-174723.1pp | -9301.9%+1890.4pp | -11192.3%+10144.5pp | -21336.8% | N/A |
| Return on Equity | N/A | N/A | -862.1%-786.1pp | -76.1% | N/A | -122.2%-75.9pp | -46.2%-45.2pp | -1.1% |
| Return on Assets | N/A | -105.1%-33.5pp | -71.6%-36.5pp | -35.1%+90.7pp | -125.7%-86.4pp | -39.3%-12.3pp | -26.9%-26.2pp | -0.8% |
| Current Ratio | 0.30-0.2 | 0.53-0.6 | 1.13-0.7 | 1.86+1.3 | 0.51-10.7 | 11.19-4.5 | 15.64+4.1 | 11.59 |
| Debt-to-Equity | -1.68+0.4 | -2.12-13.2 | 11.04+9.9 | 1.17+9.2 | -8.07-10.2 | 2.11+1.4 | 0.72+0.6 | 0.11 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$24.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.30), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Ayala Pharm's annual revenue?
Ayala Pharm (ADXS) reported $13K in total revenue for fiscal year 2023. This represents a -98.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ayala Pharm's revenue growing?
Ayala Pharm (ADXS) revenue declined by 98.1% year-over-year, from $692K to $13K in fiscal year 2023.
Is Ayala Pharm profitable?
No, Ayala Pharm (ADXS) reported a net income of -$48.1M in fiscal year 2023, with a net profit margin of -369784.6%.
What is Ayala Pharm's EBITDA?
Ayala Pharm (ADXS) had EBITDA of -$35.9M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ayala Pharm's gross margin?
Ayala Pharm (ADXS) had a gross margin of 0.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ayala Pharm's operating margin?
Ayala Pharm (ADXS) had an operating margin of -278969.2% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Ayala Pharm's net profit margin?
Ayala Pharm (ADXS) had a net profit margin of -369784.6% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Ayala Pharm's operating cash flow?
Ayala Pharm (ADXS) generated -$29.5M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Ayala Pharm's total assets?
Ayala Pharm (ADXS) had $16.6M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does Ayala Pharm spend on research and development?
Ayala Pharm (ADXS) invested $24.1M in research and development during fiscal year 2023.
What is Ayala Pharm's current ratio?
Ayala Pharm (ADXS) had a current ratio of 0.30 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Ayala Pharm's debt-to-equity ratio?
Ayala Pharm (ADXS) had a debt-to-equity ratio of -1.68 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ayala Pharm's return on assets (ROA)?
Ayala Pharm (ADXS) had a return on assets of -290.0% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Ayala Pharm's cash runway?
Based on fiscal year 2023 data, Ayala Pharm (ADXS) had $4.9M in cash against an annual operating cash burn of $29.5M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Ayala Pharm's debt-to-equity ratio negative or unusual?
Ayala Pharm (ADXS) has negative shareholder equity of -$24.4M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Ayala Pharm's Piotroski F-Score?
Ayala Pharm (ADXS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ayala Pharm's earnings high quality?
Ayala Pharm (ADXS) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ayala Pharm?
Ayala Pharm (ADXS) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.